Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018102612) ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/102612 International Application No.: PCT/US2017/064075
Publication Date: 07.06.2018 International Filing Date: 30.11.2017
IPC:
C12N 15/66 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
66
General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Applicants:
JUNO THERAPEUTICS, INC. [US/US]; 400 Dexter Ave. North Suite 1200 Seattle, WA 98109, US
Inventors:
LEVITSKY, Hyam I.; US
Agent:
AIKEN, Charity; US
ARJOMAND, Mehran; US
BASOL, Erol, C.; US
AHN, Sejin; US
BANKO, Max; US
Priority Data:
62/429,70902.12.2016US
Title (EN) ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODS
(FR) CELLULES B MODIFIÉES ET COMPOSITIONS ET MÉTHODES ASSOCIÉES
Abstract:
(EN) Provided herein are engineered B cells, such as for adoptive cell therapy. In some aspects, also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some embodiments, the cells are engineered to produce and/or secrete an exogenous protein, such as a therapeutic protein, including antibodies and antigen-binding fragments thereof. In some aspects, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence of the cells.
(FR) La présente invention concerne des cellules B modifiées, par exemple pour une thérapie cellulaire adoptive. L'invention concerne également des méthodes et des compositions pour modifier et produire lesdites cellules, des compositions contenant les cellules, et des méthodes pour leur administration à des sujets. Dans certains modes de réalisation, les cellules sont modifiées pour produire et/ou sécréter une protéine exogène, telle qu'une protéine thérapeutique, comprenant des anticorps et des fragments de liaison à l'antigène associés. Dans certains modes de réalisation, les caractéristiques des cellules et des méthodes permettent d'obtenir une augmentation ou une amélioration de l'activité, de l'efficacité et/ou de la persistance des cellules.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)